Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma
NASHVILLE, Tenn. — Building on the existing immune checkpoint inhibitor (ICI) platform, new treatment strategies for renal cell carcinoma (RCC) seek to adapt the cancer’s immunity cycle to inform development of more effective therapies, according to a review presented here. Limited options exist beyond anti-VEGF and ICI-based strategies for patients with advanced disease, particularly those […]